Form 4: Disc Medicine CEO John Quisel Reports Acquisition of Shares and Stock Options

CEO John Quisel reports acquisition of common stock and stock options in Disc Medicine, Inc.

Summary

• On February 10, 2025, John D Quisel, CEO of Disc Medicine, Inc., reported acquiring 78,337 shares of common stock and stock options for 117,505 shares.
• The common stock was acquired at a price of $0.
• Quisel now directly owns 160,402 shares of common stock following the transaction.
• The stock options have an exercise price of $54.71 and expire on February 9, 2035.
• The shares underlying the option vest monthly over 48 months starting March 10, 2025.
• The restricted stock units (RSUs) vest annually in four 25% installments commencing on February 15, 2026.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing. The CEO's acquisition could be seen as slightly positive, but it's not a strong indicator.

Positives

• The CEO's acquisition of shares and options could be seen as a positive signal, indicating confidence in the company's future prospects.

Risks

• The vesting schedules for the stock options and RSUs are contingent on the Reporting Person's continued service, which introduces a risk factor related to personnel retention.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules suggest a continued commitment from the CEO.

Industry Context

Form 4 filings are standard disclosures for company insiders and provide transparency into their transactions, which can influence investor sentiment.

Stakeholder Impact

• The CEO's stock acquisition could positively influence shareholder confidence.

Key Dates

Keywords

Disc Medicine, IRON, John Quisel, CEO, stock options, common stock, Form 4, acquisition, RSUs, vesting